SALT LAKE CITY, Utah, Nov. 3 /PRNewswire-FirstCall/ -- Grant Life Sciences, Inc., (BULLETIN BOARD: GRTV) announced an agreement with Allogen Laboratories, a wholly owned subsidiary of the Cleveland Clinic Foundation, wherein Allogen will perform testing and validation studies on Grant's protein based HPV/cervical cancer diagnostic technology and kits.
As a part of the agreement, Allogen will screen pre-cancerous and cervical cancer patient samples over Grant's proprietary test to determine the efficacy of the technology. The test, which consists of synthetic peptides derived from Human Papillomavirus proteins, would be the first direct diagnostic to directly detect cervical cancer.
Dr. Daniel Cook, Director of Allogen Laboratories, stated, "We are very excited about this opportunity to participate in the validation process of this potentially very significant diagnostic test. It's a great opportunity to explore the potential of new technologies in order to overcome the limitations of current methodologies."
Stan Yakatan, Chairman and CEO of Grant Ventures, stated, "We are thrilled to be working with a high quality group like the Cleveland Clinic, which is a strong validation for the cervical cancer diagnostic under development. The market for cervical cancer testing is enormous and Allogen Laboratories will aid in the speed and quality of our development plans for our non-invasive, protein-based diagnostic."
The human papillomavirus (HPV) causes virtually all cervical cancer. Through a proprietary protein-based technology, the assay under development by Grant looks at HPV in a fashion that identifies cervical cancer, its precursors or the likelihood of its presence. This immunotest, in which antibodies especially associated with HPV-caused neoplasias or cancers are detected with synthetic, proprietary peptides or amino acid sequences derived from certain proteins in the human papillomavirus.
About Allogen Laboratories
Allogen Laboratories, a wholly owned subsidiary of the Cleveland Clinic Foundation, performs a wide variety of diagnostic development and high complexity diagnostic and transplant testing for many areas within the Cleveland Clinic Foundation.
About Grant Ventures, Inc.
Grant Ventures, Inc. develops products to improve the efficiency of diagnosing cervical cancer. The Company currently is developing protein-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. This screening test analyzes blood for the presence of certain antibodies that appear only when cervical cancer or certain pre-cancerous conditions are present. Invasive cervical cancer kills approximately 300,000 women annually. Currently, there are more than 120 million cervical screening tests administered annually in the United States and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears and globally 1.7 billion women over the age of 20 do not undergo regular cervical cancer testing.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see our filings with the Securities and Exchange Commission.
Grant Life Sciences, Inc.